Investors Research Corp Raises Stock Position in Pfizer Inc. (NYSE:PFE)

Investors Research Corp increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,058 shares of the biopharmaceutical company’s stock after purchasing an additional 720 shares during the period. Investors Research Corp’s holdings in Pfizer were worth $900,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Heritage Way Advisors LLC raised its holdings in shares of Pfizer by 0.6% during the second quarter. Heritage Way Advisors LLC now owns 57,524 shares of the biopharmaceutical company’s stock worth $2,492,000 after purchasing an additional 354 shares during the last quarter. Natixis acquired a new stake in Pfizer during the second quarter valued at $258,466,000. Machina Capital S.A.S. grew its position in Pfizer by 14.4% during the second quarter. Machina Capital S.A.S. now owns 43,837 shares of the biopharmaceutical company’s stock valued at $1,899,000 after buying an additional 5,522 shares during the period. Integrated Wealth Concepts LLC grew its position in Pfizer by 14.2% during the second quarter. Integrated Wealth Concepts LLC now owns 68,060 shares of the biopharmaceutical company’s stock valued at $2,840,000 after buying an additional 8,445 shares during the period. Finally, Annex Advisory Services LLC grew its position in Pfizer by 0.7% during the second quarter. Annex Advisory Services LLC now owns 51,785 shares of the biopharmaceutical company’s stock valued at $2,243,000 after buying an additional 382 shares during the period. 71.66% of the stock is owned by hedge funds and other institutional investors.

Several analysts recently commented on the stock. JPMorgan Chase & Co. raised their price target on shares of Pfizer from $37.00 to $46.00 and gave the company a “neutral” rating in a research report on Thursday, September 19th. They noted that the move was a valuation call. UBS Group restated a “neutral” rating and set a $43.00 price target on shares of Pfizer in a research report on Monday, August 5th. Morgan Stanley dropped their price target on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 27th. Credit Suisse Group restated a “neutral” rating on shares of Pfizer in a research report on Monday, August 12th. Finally, ValuEngine upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Twelve analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $44.47.

In related news, major shareholder Pfizer Inc bought 50,000 shares of the company’s stock in a transaction dated Tuesday, September 17th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $900,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Scott Gottlieb bought 3,000 shares of the company’s stock in a transaction dated Friday, August 23rd. The stock was bought at an average price of $34.72 per share, for a total transaction of $104,160.00. Following the transaction, the director now owns 3,000 shares of the company’s stock, valued at $104,160. The disclosure for this purchase can be found here. 0.09% of the stock is owned by company insiders.

Shares of NYSE PFE traded up $0.19 during trading on Tuesday, hitting $36.65. The company had a trading volume of 569,058 shares, compared to its average volume of 16,028,038. The stock has a fifty day simple moving average of $36.25 and a two-hundred day simple moving average of $39.64. Pfizer Inc. has a fifty-two week low of $33.97 and a fifty-two week high of $46.47. The firm has a market capitalization of $202.08 billion, a price-to-earnings ratio of 12.21, a price-to-earnings-growth ratio of 2.16 and a beta of 0.66. The company has a quick ratio of 1.21, a current ratio of 1.47 and a debt-to-equity ratio of 0.60.

Pfizer (NYSE:PFE) last announced its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The business had revenue of $13.26 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the business earned $0.77 earnings per share. The company’s revenue for the quarter was down 1.5% compared to the same quarter last year. On average, analysts anticipate that Pfizer Inc. will post 2.82 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a $0.36 dividend. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $1.44 annualized dividend and a dividend yield of 3.93%. Pfizer’s dividend payout ratio (DPR) is 48.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: Google Finance

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.